FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4289525295> ?p ?o ?g. }

• W4289525295 endingPage "139" @default.
• W4289525295 startingPage "127" @default.
• W4289525295 abstract "Two-thirds of patients with mucopolysaccharidosis II (MPS II; Hunter syndrome) have cognitive impairment. This phase 2/3, randomized, controlled, open-label, multicenter study (NCT02055118) investigated the effects of intrathecally administered idursulfase-IT on cognitive function in patients with MPS II. Children older than 3 years with MPS II and mild-to-moderate cognitive impairment (assessed by Differential Ability Scales-II [DAS-II], General Conceptual Ability [GCA] score) who had tolerated intravenous idursulfase for at least 4 months were randomly assigned (2:1) to monthly idursulfase-IT 10 mg (n = 34) via an intrathecal drug delivery device (IDDD; or by lumbar puncture) or no idursulfase-IT treatment (n = 15) for 52 weeks. All patients continued to receive weekly intravenous idursulfase 0.5 mg/kg as standard of care. Of 49 randomized patients, 47 completed the study (two patients receiving idursulfase-IT discontinued). The primary endpoint (change from baseline in DAS-II GCA score at week 52 in a linear mixed-effects model for repeated measures analysis) was not met: although there was a smaller decrease in DAS-II GCA scores with idursulfase-IT than with no idursulfase-IT at week 52, this was not significant (least-squares mean treatment difference [95% confidence interval], 3.0 [−7.3, 13.3]; p = 0.5669). Changes from baseline in Vineland Adaptive Behavioral Scales-II Adaptive Behavior Composite scores at week 52 (key secondary endpoint) were similar in the idursulfase-IT (n = 31) and no idursulfase-IT (n = 14) groups. There were trends towards a potential positive effect of idursulfase-IT across DAS-II composite, cluster, and subtest scores, notably in patients younger than 6 years at baseline. In a post hoc analysis, there was a significant (p = 0.0174), clinically meaningful difference in change from baseline in DAS-II GCA scores at week 52 with idursulfase-IT (n = 13) versus no idursulfase-IT (n = 6) among those younger than 6 years with missense iduronate-2-sulfatase gene variants. Overall, idursulfase-IT reduced cerebrospinal glycosaminoglycan levels from baseline by 72.0% at week 52. Idursulfase-IT was generally well tolerated. These data suggest potential benefits of idursulfase-IT in the treatment of cognitive impairment in some patients with neuronopathic MPS II. After many years of extensive review and regulatory discussions, the data were found to be insufficient to meet the evidentiary standard to support regulatory filings." @default.
• W4289525295 created "2022-08-03" @default.
• W4289525295 creator A5000620336 @default.
• W4289525295 creator A5000891412 @default.
• W4289525295 creator A5007752833 @default.
• W4289525295 creator A5010277368 @default.
• W4289525295 creator A5011620244 @default.
• W4289525295 creator A5012352667 @default.
• W4289525295 creator A5015572304 @default.
• W4289525295 creator A5023054981 @default.
• W4289525295 creator A5025219147 @default.
• W4289525295 creator A5027630774 @default.
• W4289525295 creator A5033197017 @default.
• W4289525295 creator A5033712069 @default.
• W4289525295 creator A5035104919 @default.
• W4289525295 creator A5040000547 @default.
• W4289525295 creator A5041744228 @default.
• W4289525295 creator A5049744314 @default.
• W4289525295 creator A5052285917 @default.
• W4289525295 creator A5053750627 @default.
• W4289525295 creator A5054148429 @default.
• W4289525295 creator A5054828898 @default.
• W4289525295 creator A5056155905 @default.
• W4289525295 creator A5058473675 @default.
• W4289525295 creator A5058641127 @default.
• W4289525295 creator A5059017138 @default.
• W4289525295 creator A5064154276 @default.
• W4289525295 creator A5068248790 @default.
• W4289525295 creator A5068466086 @default.
• W4289525295 creator A5069772960 @default.
• W4289525295 creator A5076973291 @default.
• W4289525295 creator A5078813133 @default.
• W4289525295 creator A5082665224 @default.
• W4289525295 creator A5085150364 @default.
• W4289525295 creator A5085315279 @default.
• W4289525295 creator A5085902845 @default.
• W4289525295 date "2022-09-01" @default.
• W4289525295 modified "2023-10-16" @default.
• W4289525295 title "Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study" @default.
• W4289525295 cites W1982093927 @default.
• W4289525295 cites W1989295722 @default.
• W4289525295 cites W1993027304 @default.
• W4289525295 cites W1997831257 @default.
• W4289525295 cites W2001925765 @default.
• W4289525295 cites W2020409398 @default.
• W4289525295 cites W202348765 @default.
• W4289525295 cites W2027292988 @default.
• W4289525295 cites W2034511507 @default.
• W4289525295 cites W2044026349 @default.
• W4289525295 cites W2091858933 @default.
• W4289525295 cites W2102067858 @default.
• W4289525295 cites W2110090942 @default.
• W4289525295 cites W2115034909 @default.
• W4289525295 cites W2134923697 @default.
• W4289525295 cites W2148584888 @default.
• W4289525295 cites W2150999708 @default.
• W4289525295 cites W2160708072 @default.
• W4289525295 cites W2172144803 @default.
• W4289525295 cites W2345935183 @default.
• W4289525295 cites W2552563917 @default.
• W4289525295 cites W2617895008 @default.
• W4289525295 cites W2618390676 @default.
• W4289525295 cites W2621808673 @default.
• W4289525295 cites W2761204945 @default.
• W4289525295 cites W2910906754 @default.
• W4289525295 cites W2966275708 @default.
• W4289525295 cites W2972531075 @default.
• W4289525295 cites W2996307640 @default.
• W4289525295 cites W3006540808 @default.
• W4289525295 cites W3027168293 @default.
• W4289525295 cites W3207770519 @default.
• W4289525295 cites W3210406894 @default.
• W4289525295 cites W4200341303 @default.
• W4289525295 cites W4239267740 @default.
• W4289525295 cites W4289528286 @default.
• W4289525295 doi "https://doi.org/10.1016/j.ymgme.2022.07.017" @default.
• W4289525295 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36027721" @default.
• W4289525295 hasPublicationYear "2022" @default.
• W4289525295 type Work @default.
• W4289525295 citedByCount "7" @default.
• W4289525295 countsByYear W42895252952022 @default.
• W4289525295 countsByYear W42895252952023 @default.
• W4289525295 crossrefType "journal-article" @default.
• W4289525295 hasAuthorship W4289525295A5000620336 @default.
• W4289525295 hasAuthorship W4289525295A5000891412 @default.
• W4289525295 hasAuthorship W4289525295A5007752833 @default.
• W4289525295 hasAuthorship W4289525295A5010277368 @default.
• W4289525295 hasAuthorship W4289525295A5011620244 @default.
• W4289525295 hasAuthorship W4289525295A5012352667 @default.
• W4289525295 hasAuthorship W4289525295A5015572304 @default.
• W4289525295 hasAuthorship W4289525295A5023054981 @default.
• W4289525295 hasAuthorship W4289525295A5025219147 @default.
• W4289525295 hasAuthorship W4289525295A5027630774 @default.
• W4289525295 hasAuthorship W4289525295A5033197017 @default.
• W4289525295 hasAuthorship W4289525295A5033712069 @default.
• W4289525295 hasAuthorship W4289525295A5035104919 @default.
• W4289525295 hasAuthorship W4289525295A5040000547 @default.
• W4289525295 hasAuthorship W4289525295A5041744228 @default.

• next